Replies to post #665321 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Elios Trial not really randomized.

prior immunotherapy (36.6% for placebo, 39.8% for both TLPLDC and TLPLDC+G, and 83.7% for TLPO;

https://ecee9cc0-9b43-4860-bf98-e43195ceb884.usrfiles.com/ugd/ecee9c_f050175ac5a1469d9e5b928bd1494372.pdf

SMH

Melanoma is what Opdivo (checkpoint inhibitor) cut its teeth on. Easiest target, highly mutated and accessible.

[skitahoe]

Abeta, very few trials give discernable data in 6 months, often not even a year. Why? Because not that many patients enroll in a trial that quickly and even the SOC often has patients living many months, often years on a variety of therapeutics. The reason so many trials last a decade or longer is that it takes that long to get data the regulators are satisfied with. Don't get me wrong, once you have an approval, it's probably faster to expand the label, but six months would be unusually fast IMHO.

Gary